{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:11:26Z","timestamp":1792714286112,"version":"4.5.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The Fc regions of antibodies mediate important effector cell functions such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP), and complement-dependent cytotoxicity (CDC). These functions enhance immune defense and infected cell clearance. This study evaluated the effect COVID-19 XBB.1.5 booster vaccination on Fc-effector antibody responses to SARS-CoV-2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We developed four assays to evaluate the Fc-effector functions of SARS-CoV-2 antibodies. ADCC and CDC assays utilized stably transfected luciferase-based target cell lines expressing SARS-CoV-2 spike variants (Ancestral, Wu-1 Omicron XBB.1.5, and EG.5) to measure antibody-mediated lysis by effector cells. ADCP and ADNP were assessed by flow cytometry to measure phagocytosis of fluorescently labeled virus-like particles that display SARS-CoV-2 variant spike proteins. Serum samples from 20 healthy adult volunteers pre- and post-monovalent XBB.1.5 COVID-19 vaccine were analyzed for pseudovirus neutralizing and Fc-effector antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Prior to administration of the COVID-19 XBB.1.5 booster vaccination, cross-neutralizing antibodies against XBB.1.5 and EG.5 variants were minimally detectable, while cross-functional Fc-effector antibodies were present at higher baseline levels. The COVID-19 XBB.1.5 booster vaccination significantly boosted both neutralizing and Fc-effector antibodies in magnitude and breadth. The greatest increase in neutralizing antibodies was against the XBB.1.5 strain, while Fc-effector functional antibodies had similar fold-increases in antibody titers against the breadth of SARS-CoV-2 variants tested. Neutralizing and Fc-effector antibodies were most highly correlated at baseline (prior to booster vaccination) but were less correlated post-vaccination, consistent with differential boosting of neutralizing vs Fc-effector antibodies by the monovalent vaccine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The COVID-19 XBB.1.5 booster vaccination significantly improved the magnitude, breadth, and quality of antibody responses to SARS-CoV-2. Combining Fc-mediated functional and neutralizing antibody assays provides a more comprehensive model for understanding vaccine-induced immunity and optimizing vaccination strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1571835","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:05:34Z","timestamp":1747735534000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Fc-effector functional antibody assays for SARS-CoV-2 variants of concern"],"prefix":"10.3389","volume":"16","author":[{"given":"Xuemin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ciric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theda","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Rostad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"111544","DOI":"10.1016\/j.celrep.2022.111544","article-title":"BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age","volume":"41","author":"Bates","year":"2022","journal-title":"Cell Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1038\/s41467-022-31615-7","article-title":"Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains","volume":"13","author":"Case","year":"2022","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"110368","DOI":"10.1016\/j.celrep.2022.110368","article-title":"A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection","volume":"38","author":"Beaudoin-Bussieres","year":"2022","journal-title":"Cell Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.immuni.2022.01.001","article-title":"mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern","volume":"55","author":"Kaplonek","year":"2022","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.05.429759","article-title":"Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M vaccination","author":"Gorman","year":"2021","journal-title":"bioRxiv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e29793","DOI":"10.1002\/jmv.29793","article-title":"Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines","volume":"96","author":"Reinig","year":"2024","journal-title":"J Med Virol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3390\/v15091926","article-title":"Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine","volume":"15","author":"Tauzin","year":"2023","journal-title":"Viruses"},{"key":"B8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.chom.2021.12.004","article-title":"Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses","volume":"30","author":"Tauzin","year":"2022","journal-title":"Cell Host Microbe"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3390\/v15061274","article-title":"A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose","volume":"15","author":"Beaudoin-Bussieres","year":"2023","journal-title":"Viruses"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn9243","article-title":"Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines","volume":"14","author":"Bartsch","year":"2022","journal-title":"Sci Transl Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00430-023-00773-w","article-title":"Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants","volume":"212","author":"Haycroft","year":"2023","journal-title":"Med Microbiol Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00101-1","article-title":"Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study","volume":"10","author":"Tartof","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.22.473880","article-title":"SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster","author":"Lusvarghi","year":"2021","journal-title":"bioRxiv"},{"key":"B14","doi-asserted-by":"publisher","first-page":"103944","DOI":"10.1016\/j.ebiom.2022.103944","article-title":"Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies","volume":"78","author":"Tada","year":"2022","journal-title":"EBioMed"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268767","article-title":"Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron","volume":"17","author":"Teng","year":"2022","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"114684","DOI":"10.1016\/j.celrep.2024.114684","article-title":"SARS-CoV-2 infection prior to vaccination amplifies Fc-mediated humoral profiles in an age-dependent manner","volume":"43","author":"Jung","year":"2024","journal-title":"Cell Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1038\/s41467-023-39189-8","article-title":"Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination","volume":"14","author":"Tong","year":"2023","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"114645","DOI":"10.1016\/j.celrep.2024.114645","article-title":"Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses","volume":"43","author":"Paciello","year":"2024","journal-title":"Cell Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj9945","article-title":"Waning immunity and IgG4 responses following bivalent mRNA boosting","volume":"10","author":"Lasrado","year":"2024","journal-title":"Sci Adv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11896","DOI":"10.1038\/s41598-024-62874-7","article-title":"Functional antibody responses targeting the Spike protein of SARS-CoV-2 Omicron XBB.1.5 in elderly nursing home residents following Wuhan-Hu-1-based mRNA booster vaccination","volume":"14","author":"Sanchez-Simarro","year":"2024","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/vaccines11111643","article-title":"SARS-CoV-2 antibody profiles in maternal serum and breast milk following mRNA COVID-19 vaccination: A longitudinal prospective observational cohort study","volume":"11","author":"Hsiao","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac215","article-title":"Functional antibody responses to severe acute respiratory syndrome coronavirus 2 variants in children with coronavirus disease 2019, multisystem inflammatory syndrome in children, and after two doses of BNT162b2 vaccination","volume":"226","author":"Rostad","year":"2022","journal-title":"J Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"ofad167","DOI":"10.1093\/ofid\/ofad167","article-title":"Longitudinal neutralizing and functional antibody responses to severe acute respiratory syndrome coronavirus 2 variants following messenger RNA coronavirus disease 2019 vaccination","volume":"10","author":"Chen","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"112900","DOI":"10.1016\/j.jim.2020.112900","article-title":"Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay","volume":"488","author":"Chen","year":"2021","journal-title":"J Immunol Methods"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2021.03.009","article-title":"The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein","volume":"559","author":"Chen","year":"2021","journal-title":"Virol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41467-023-44265-0","article-title":"Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques","volume":"15","author":"Sankhala","year":"2024","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-023-01359-1","article-title":"Fc-gammaR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2","volume":"8","author":"Mackin","year":"2023","journal-title":"Nat Microbiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","volume":"184","author":"Winkler","year":"2021","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2024.06.003","article-title":"Protective non-neutralizing SARS-CoV-2 monoclonal antibodies","volume":"45","author":"Izadi","year":"2024","journal-title":"Trends Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2314730121","article-title":"High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies","volume":"121","author":"Paciello","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100296","DOI":"10.1016\/j.xcrm.2021.100296","article-title":"Decay of Fc-dependent antibody functions after mild to moderate COVID-19","volume":"2","author":"Lee","year":"2021","journal-title":"Cell Rep Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1571835\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:05:35Z","timestamp":1747735535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1571835\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2025.1571835"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1571835","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"article-number":"1571835"}}